Physician profile
John C Freeman
NPI 1437279031
$1,479.91
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $80.16 · 2021: $81.00 · 2022: $585 · 2023: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $137.19 | 2020-2022 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $120.47 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $116.75 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $110.64 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $108.65 | 2022-2023 | |
| Amgen INC. | $91.70 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $83.10 | 2022 | |
| Novo Nordisk INC | $72.63 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $66.82 | 2019-2022 | |
| Medtronic, INC. | $62.40 | 2022 | |
| Exact Sciences Corporation | $60.37 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $48.76 | 2023 | |
| Abbvie INC. | $47.81 | 2023 | |
| Corium, LLC | $43.82 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.61 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.50 | 2019 | |
| Glaxosmithkline, LLC. | $22.66 | 2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $21.78 | 2019 | |
| Allergan, INC. | $21.49 | 2019 | |
| Halozyme INC | $20.75 | 2023 | |
| Antares Pharma, INC. | $19.97 | 2023 | Nocdurna, Xyosted, Tlando |
| Abbott Laboratories | $18.92 | 2022 | |
| Merck Sharp & Dohme LLC | $18.41 | 2019 | |
| Lucid Diagnostics INC. | $15.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.37 | 2022 | |
| Amarin Pharma, INC. | $13.30 | 2020 | |
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.80 | 2019 | |
| Astellas Pharma US INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.